AG
CADX

Aperio Group’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Aperio Group’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-12,092
Closed -$87.3K – 1897
2013
Q3 		$76K Sell
12,092
-259
-2% -$1.65K ﹤0.01% 1748
2013
Q2 		$84K Buy
+12,351
New +$86K ﹤0.01% 1604

Other funds holding CADX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Aperio Group's CADX Position: Q4 2013 in Review

Aperio Group sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q4 2013, closing a stake of 12,092 shares — an estimated $87.3K sold.

Aperio Group first reported a position in CADX in Q2 2013 and held it in 2 quarters. The position peaked at $84K in Q2 2013. 100 funds tracked by Wall St. Rank hold CADX as of Q4 2013.

  • Aperio Group reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q4 2013 after selling out during the quarter.
  • Aperio Group sold 12,092 CADENCE PHARMACEUTICALS, INC COM STK shares in Q4 2013, an estimated $87.3K.
  • Aperio Group first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 2 quarters.
  • Aperio Group's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $84K in Q2 2013.
  • 100 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q4 2013.

Based on Aperio Group's 13F filing for Q4 2013, filed 30 Jan 2014.